Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease

Crohn’s disease (CD) is characterized by malfunction of immune-regulatory mechanisms with disturbed intestinal mucosal homeostasis and increased activation of mucosal immune cells, leading to abnormal secretion of numerous pro- and anti-inflammatory mediators. MCP2/CCL8 is produced by intestinal epi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kader Irak, Mehmet Bayram, Sami Cifci, Gulsen Sener
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/72749a6f684e428091c2343bdb30d1be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:72749a6f684e428091c2343bdb30d1be
record_format	dspace
spelling	oai:doaj.org-article:72749a6f684e428091c2343bdb30d1be2021-11-25T06:13:53ZSerum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease1932-6203https://doaj.org/article/72749a6f684e428091c2343bdb30d1be2021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598053/?tool=EBIhttps://doaj.org/toc/1932-6203Crohn’s disease (CD) is characterized by malfunction of immune-regulatory mechanisms with disturbed intestinal mucosal homeostasis and increased activation of mucosal immune cells, leading to abnormal secretion of numerous pro- and anti-inflammatory mediators. MCP2/CCL8 is produced by intestinal epithelial cells and macrophages, and is a critical regulator of mucosal inflammation. NLRC4 is expressed in phagocytes and intestinal epithelial cells and is involved in intestinal homeostasis and host defense. However, no study to date has assessed the circulating levels of NLRC4 and MCP2/CCL8 in patients with CD. The study was aimed to investigate the serum levels of MCP2/CCL8 and NLRC4 in patients with active CD. Sixty-nine patients with active CD and 60 healthy participants were included in the study. Serum levels of NLRC4 and MCP2/CCL8 were determined using an enzyme-linked immunosorbent assay. The median serum NLRC4 levels were lower in the patient group than in the controls (71.02 (range, 46.59–85.51) pg/mL vs. 99.43 (range 83.52–137.79) pg/mL) (P < 0.001). The median serum levels of MCP2/CCL8 were decreased in patients with CD (28.68 (range, 20.16–46.0) pg/mL) compared with the controls (59.96 (range, 40.22–105.59) pg/mL) (P < 0.001). Cut-off points of NLRC4 (<81 pg/mL) and MCP2/CCL8 (<40 pg/mL) showed high sensitivity and specificity for identifying active CD. In conclusion, this is the first study to examine circulating levels of MCP2/CCL8 and NLRC4 in patients with active CD. Our results suggest that serum NLRC4 and MCP2/CCL8 levels may be involved in the pathogenesis of CD and may have a protective effect on intestinal homeostasis and inflammation. Serum levels of MCP2/CCL8 and NLRC4 could be used as a diagnostic tool and therapeutic target for CD.Kader IrakMehmet BayramSami CifciGulsen SenerPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kader Irak Mehmet Bayram Sami Cifci Gulsen Sener Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
description	Crohn’s disease (CD) is characterized by malfunction of immune-regulatory mechanisms with disturbed intestinal mucosal homeostasis and increased activation of mucosal immune cells, leading to abnormal secretion of numerous pro- and anti-inflammatory mediators. MCP2/CCL8 is produced by intestinal epithelial cells and macrophages, and is a critical regulator of mucosal inflammation. NLRC4 is expressed in phagocytes and intestinal epithelial cells and is involved in intestinal homeostasis and host defense. However, no study to date has assessed the circulating levels of NLRC4 and MCP2/CCL8 in patients with CD. The study was aimed to investigate the serum levels of MCP2/CCL8 and NLRC4 in patients with active CD. Sixty-nine patients with active CD and 60 healthy participants were included in the study. Serum levels of NLRC4 and MCP2/CCL8 were determined using an enzyme-linked immunosorbent assay. The median serum NLRC4 levels were lower in the patient group than in the controls (71.02 (range, 46.59–85.51) pg/mL vs. 99.43 (range 83.52–137.79) pg/mL) (P < 0.001). The median serum levels of MCP2/CCL8 were decreased in patients with CD (28.68 (range, 20.16–46.0) pg/mL) compared with the controls (59.96 (range, 40.22–105.59) pg/mL) (P < 0.001). Cut-off points of NLRC4 (<81 pg/mL) and MCP2/CCL8 (<40 pg/mL) showed high sensitivity and specificity for identifying active CD. In conclusion, this is the first study to examine circulating levels of MCP2/CCL8 and NLRC4 in patients with active CD. Our results suggest that serum NLRC4 and MCP2/CCL8 levels may be involved in the pathogenesis of CD and may have a protective effect on intestinal homeostasis and inflammation. Serum levels of MCP2/CCL8 and NLRC4 could be used as a diagnostic tool and therapeutic target for CD.
format	article
author	Kader Irak Mehmet Bayram Sami Cifci Gulsen Sener
author_facet	Kader Irak Mehmet Bayram Sami Cifci Gulsen Sener
author_sort	Kader Irak
title	Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_short	Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_full	Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_fullStr	Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_full_unstemmed	Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_sort	serum levels of nlrc4 and mcp-2/ccl8 in patients with active crohn’s disease
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/72749a6f684e428091c2343bdb30d1be
work_keys_str_mv	AT kaderirak serumlevelsofnlrc4andmcp2ccl8inpatientswithactivecrohnsdisease AT mehmetbayram serumlevelsofnlrc4andmcp2ccl8inpatientswithactivecrohnsdisease AT samicifci serumlevelsofnlrc4andmcp2ccl8inpatientswithactivecrohnsdisease AT gulsensener serumlevelsofnlrc4andmcp2ccl8inpatientswithactivecrohnsdisease
_version_	1718413990240976896

Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease

Ejemplares similares